Dependence of<i>Staphylococcus epidermidis</i>on non-transferrin-bound iron for growth

Matinaho, Sanna; Bonsdorff, Leni von; Rouhiainen, Ari; Lönnroth, M.; Parkkinen, Jaakko

doi:10.1111/j.1574-6968.2001.tb10561.x

Cited by 27 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trivier and Courcol reported that S. aureus could grow in severely iron-limited media containing 0.04 µM Fe whereas other bacteria could not (35). Martinaho et al also found that the growth initiation of S. epidermidis is dependent on the presence of readily-available iron, i.e., non-transferrin-bound-iron (10). According to the results of the present study, S. aureus grew more actively in SSD broths containing FC or HT and utilized iron from transferrin more efficiently than S. epidermidis or S. saprophyticus (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…In vivo bacterial growth can be stimulated by increased iron-availability, and conversely, bacterial growth can be suppressed by reducing iron-availability. Coagulase-negative staphylococci (CoNS), especially S. epidermidis , are known to be major causative agents of septicemia in patients who have received anticancer chemotherapy or stem cell transplantation, because serum iron levels are elevated in these patients (8-10). Recently, it was reported that S. epidermidis infections in such patients can be prevented by administering human apotransferrin, which is a major iron-withholding protein (11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci

Kim

Shin

2009

J Korean Med Sci

View full text Add to dashboard Cite

The standard iron-chelator deferoxamine is known to prevent the growth of coagulase-negative staphylococci (CoNS) which are major pathogens in iron-overloaded patients. However, we found that deferoxamine rather promotes the growth of coagulase-positive Staphylococcus aureus. Accordingly, we tested whether deferiprone, a new clinically-available iron-chelator, can prevent the growth of S. aureus strains as well as CoNS. Deferiprone did not at least promote the growth of all S. aureus strains (n=26) and CoNS (n=27) at relatively low doses; moreover, it could significantly inhibit the growth of all staphylococci on non-transferrin-bound-iron and the growth of all CoNS on transferrin-bound iron at relatively high doses. At the same doses, it did not at least promote the growth of all S. aureus strains on transferrin-bound-iron. These findings indicate that deferiprone can be useful to prevent staphylococcal infections, as well as to improve iron overload, in iron-overloaded patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci

Kim

Shin

2009

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…In another study, the growth of S. epidermidis was inhibited in the presence of the chelator and the inhibitory effect was removed when iron was introduced (35). Anyway, S. epidermidis exhibits a better growth in the patients with increased blood iron (36), and therefore this finding could not be considered surprising. On the other hand, S. epidermidis could be susceptible to the chelator and gene variations probably have not yet been developed to give this property to S. epidermidis.…”

Section: Discussionmentioning

confidence: 99%

In vitro effect of iron chelators on the growth of Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus, Yersinia enterocolitica, and Pseudomonas aeruginosa Strains

Fekri

Khoshdel

Rasoulynezhad

et al. 2019

J Shahrekord Univ Med Sci

View full text Add to dashboard Cite

Background and aims:Thalassemia patients are predisposed to septicemia due to iron overload. The iron chelators have a potential role in the treatment of septicemia. This study was conducted to investigate the in vitro effect of iron chelators, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFS) on the growth of effective bacteria (Staphylococcus aureus, Yersinia enterocolitica, and Pseudomonas aeruginosa) and their synergistic effect with each other and antibiotics. Materials and Methods: Five bacterial strains were incubated in the presence of seven chelators in Mueller Hinton agar and the number of colonies was recorded for each sample. Antibiotic discs were placed in the plates. Susceptibility to antibiotics was assessed by disc diffusion method (Kirby-Bauer test) and also the zone inhibition around the disc was measured in mm after incubating the relevant plate at 37°C for a day. Results: The growth of all the studied bacteria increased in the presence of iron and was inhibited in the presence of different chelators. Chelators and antibiotics had synergistic effects on growth inhibition of Escherichia coli, S. aureus, and P. aeruginosa in culture medium, while the growth inhibition of Y. enterocolitica was seen in the presence of deferiprone and deferasirox combination. Conclusion: Chelators in combination with antibiotics exert synergistic effects on growth inhibition of prevalent bacteria (except for Y. enterocolitica).

show abstract

“…Pathogenic bacterial development is strongly dependent on the presence of iron, as evidenced by their highly orchestrated mechanisms of acquiring iron, including heme uptake systems and secretion of siderophores to bind excess ferric iron [ 27 ]. High TSAT and the presence of plasma NTBI are associated with enhanced growth of siderophilic bacteria [ 28 – 30 ]. Iron availability is thus at the heart of the battle between infectious pathogens and host defenses [ 31 ].…”

Section: Iron: a Double-edged Swordmentioning

confidence: 99%

Iron as an emerging therapeutic target in critically ill patients

Grange,

Lux,

Brichart

et al. 2023

Crit Care

View full text Add to dashboard Cite

The multiple roles of iron in the body have been known for decades, particularly its involvement in iron overload diseases such as hemochromatosis. More recently, compelling evidence has emerged regarding the critical role of non-transferrin bound iron (NTBI), also known as catalytic iron, in the care of critically ill patients in intensive care units (ICUs). These trace amounts of iron constitute a small percentage of the serum iron, yet they are heavily implicated in the exacerbation of diseases, primarily by catalyzing the formation of reactive oxygen species, which promote oxidative stress. Additionally, catalytic iron activates macrophages and facilitates the growth of pathogens. This review aims to shed light on this underappreciated phenomenon and explore the various common sources of NTBI in ICU patients, which lead to transient iron dysregulation during acute phases of disease. Iron serves as the linchpin of a vicious cycle in many ICU pathologies that are often multifactorial. The clinical evidence showing its detrimental impact on patient outcomes will be outlined in the major ICU pathologies. Finally, different therapeutic strategies will be reviewed, including the targeting of proteins involved in iron metabolism, conventional chelation therapy, and the combination of renal replacement therapy with chelation therapy.

show abstract

Dependence ofStaphylococcus epidermidison non-transferrin-bound iron for growth

Cited by 27 publications

References 20 publications

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci

In vitro effect of iron chelators on the growth of Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus, Yersinia enterocolitica, and Pseudomonas aeruginosa Strains

Iron as an emerging therapeutic target in critically ill patients

Contact Info

Product

Resources

About